Name: | etoricoxib |
---|---|
PubChem Compound ID: | 11537731 |
Molecular formula: | C18H15ClN2O2S |
Molecular weight: | 357.843 g/mol |
Name: | etoricoxib |
---|---|
Name (isomeric): | DB01628 |
Drug Type: | small molecule |
Synonyms: |
MK-663
|
Brand: | Tauxib, Arcoxia, Nucoxia, Algix |
Category: | Cyclooxygenase Inhibitors |
CAS number: | 202409-33-4 |
Indication: | For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. |
---|---|
Pharmacology: | Etoricoxib is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1). Currently it is approved in more than 60 countries worldwide but not in the US, where the Food and Drug Administration (FDA) require additional safety and efficacy data for etoricoxib before it will issue approval. |
Mechanism of Action: | Like any other COX-2 selective inhibitor Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces prostaglandins (PGs) generation from arachidonic acid. |
Absorption: | Bioavailability is 100% following oral administration. |
Protein binding: | 92% |
Biotransformation: | Hepatic, primarily via CYP3A4. |
Half Life: | 22 hours |
Toxicity: | This reduced activity is the cause of reduced gastrointestinal toxicity, as demonstrated in several large clinical trials performed with different COXIB (see below links on NEJM and The Lancet). Some clinical trials and meta-analysis showed that treatment with COXIB lead to increased incidence of cardiovascular adverse events compared to placebo |
Affected organisms: | Humans and other mammals |
Food interaction: |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug interaction: |
|